T cell cytokine imbalance towards production of IFN‐γ and IL‐10 in NZB/W F1 lupus‐prone mice is associated with autoantibody levels and nephritis

References

• Mosmann T. R., Coffman R. L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145–73
   PubMed Web of Science ®Google Scholar
• Gomez D., Correa P. A., Gomez L. M., Cadena J., Molina J. F., Anaya J. M. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?. Semin Arthritis Rheum 2004; 33: 404–13
   PubMed Web of Science ®Google Scholar
• Min D. J., Cho M. L., Cho C. S., Min S. Y., Kim W. U., Yang S. Y., et al. Decreased production of interleukin‐12 and interferon‐gamma is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol 2001; 30: 159–63
   PubMed Web of Science ®Google Scholar
• Amerio P., Frezzolini A., Abeni D., Teofoli P., Girardelli C. R., De Pita O., et al. Increased IL‐18 in patients with systemic lupus erythematosus: relations with Th‐1, Th‐2, pro‐inflammatory cytokines and disease activity. IL‐18 is a marker of disease activity but does not correlate with pro‐inflammatory cytokines. Clin Exp Rheumatol 2002; 20: 535–8
   PubMed Web of Science ®Google Scholar
• Csiszar A., Nagy G., Gergely P., Pozsonyi T., Pocsik E. Increased interferon‐gamma (IFN‐gamma), IL‐10 and decreased IL‐4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2000; 122: 464–70
   PubMed Web of Science ®Google Scholar
• Richaud‐Patin Y., Alcocer‐Varela J., Llorente L. High levels of Th2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin 1995; 47: 267–72
   PubMedGoogle Scholar
• Sugimoto K., Morimoto S., Kaneko H., Nozawa K., Tokano Y., Takasaki Y., et al. Decreased IL‐4 producing CD4+ T cells in patients with active systemic lupus erythematosus – relation to IL‐12R expression. Autoimmunity 2002; 35: 381–7
   PubMed Web of Science ®Google Scholar
• Funauchi M., Ikoma S., Enomoto H., Horiuchi A. Decreased Th1‐like and increased Th2‐like cells in systemic lupus erythematosus. Scand J Rheumatol 1998; 27: 219–24
   PubMed Web of Science ®Google Scholar
• Grondal G., Gunnarsson I., Ronnelid J., Rogberg S., Klareskog L., Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000; 18: 565–70
   PubMed Web of Science ®Google Scholar
• Nagy G., Pallinger E., Antal‐Szalmas P., Aleksza M., Marschalko M., Brozik M., et al. Measurement of intracellular interferon‐gamma and interleukin‐4 in whole blood T lymphocytes from patients with systemic lupus erythematosus. Immunol Lett 2000; 74: 207–10
   PubMedGoogle Scholar
• Manolios N., Schrieber L., Nelson M., Geczy C. L. Enhanced interferon‐gamma (IFN) production by lymph node cells from autoimmune (MRL/1, MRL/n) mice. Clin Exp Immunol 1989; 76: 301–6
   PubMed Web of Science ®Google Scholar
• Takahashi S., Fossati L., Iwamoto M., Merino R., Motta R., Kobayakawa T., et al. Imbalance towards Th1 predominance is associated with acceleration of lupus‐like autoimmune syndrome in MRL mice. J Clin Invest 1996; 97: 1597–604
   PubMed Web of Science ®Google Scholar
• Hahn B. Animal models of systemic lupus erythematosus. Dubois' lupus erythematosus, 6^th edition, Philadelphia: Lippincott Williams & Wilkins. 2002:, D. J Wallace, B. H Hahn, 1993; 339–388
   Google Scholar
• Sato M. N., Minoprio P., Avrameas S., Ternynck T. Defects in the regulation of anti‐DNA antibody production in aged lupus‐prone (NZB×NZW)F1 mice: analysis of T‐cell lymphokine synthesis. Immunology 1995; 85: 26–32
   PubMedGoogle Scholar
• McMurray R. W., Hoffman R. W., Nelson W., Walker S. E. Cytokine mRNA expression in the B/W mouse model of systemic lupus erythematosus – analyses of strain, gender, and age effects. Clin Immunol Immunopathol 1997; 84: 260–8
   PubMedGoogle Scholar
• Yoshii H., Yamamoto K., Okudaira H., Dohi M., Suko M., Fukata Y., et al. Age‐related differential mRNA expression of T cell cytokines in NZB/NZW F1 mice. Lupus 1995; 4: 213–16
   PubMed Web of Science ®Google Scholar
• Lin L. C., Chen Y. C., Chou C. C., Hsieh K. H., Chiang B. L. Dysregulation of T helper cell cytokines in autoimmune proneNZB×NZW F1 mice. Scand J Immunol 1995; 42: 466–72
   PubMed Web of Science ®Google Scholar
• Ishikawa S., Akakura S., Abe M., Terashima K., Chijiiwa K., Nishimura H., et al. A subset of CD4+ T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance. J Immunol 1998; 161: 1267–73
   PubMedGoogle Scholar
• Riemekasten G., Marell J., Trebeljahr G., Klein R., Hausdorf G., Haupl T., et al. A novel epitope on the C‐terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J Clin Invest 1998; 102: 754–63
   PubMed Web of Science ®Google Scholar
• Hiepe F., Kiessig S. T., Jahn S., Volk H. D., Grunow R., Apostoloff E., et al. A sensitive and class specific solid phase enzyme immunoassay for anti‐DNA autoantibodies in supernatants of lymphocyte cultures and human hybridomas. Biomed Biochim Acta 1986; 45: K29–35
   Google Scholar
• Wiik A. Anti‐nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 2005; 34: 260–68
   PubMed Web of Science ®Google Scholar
• Lahita R. G. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999; 11: 352–6
   PubMedGoogle Scholar
• Jacob C. O., van der Meide P. H., McDevitt H. O. In vivo treatment of (NZB×NZW)F1 lupus‐like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987; 166: 798–803
   PubMed Web of Science ®Google Scholar
• Ozmen L., Roman D., Fountoulakis M., Schmid G., Ryffel B., Garotta G. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon‐gamma receptor inhibits the onset of glomerulonephritis. Eur J Immunol 1995; 25: 6–12
   PubMed Web of Science ®Google Scholar
• Haas C., Ryffel B., Le Hir M. IFN‐gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J Immunol 1997; 158: 5484–91
   PubMed Web of Science ®Google Scholar
• Balomenos D., Rumold R., Theofilopoulos A. N. Interferon‐gamma is required for lupus‐like disease and lymphoaccumulation in MRL‐lpr mice. J Clin Invest 1998; 101: 364–71
   PubMed Web of Science ®Google Scholar
• Schwarting A., Wada T., Kinoshita K., Tesch G., Kelley V. R. IFN‐gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL‐Fas(lpr) mice. J Immunol 1998; 161: 494–503
   PubMed Web of Science ®Google Scholar
• Peng S. L., Moslehi J., Craft J. Roles of interferon‐gamma andinterleukin‐4 in murine lupus. J Clin Invest 1997; 99: 1936–46
   PubMed Web of Science ®Google Scholar
• Sugiyama M., Funauchi M., Yamagata T., Nozaki Y., Yoo B., Ikoma S., et al. Predominant inhibition of Th1 cytokines in New Zealand black/white F1 mice treated with FK506. Scand J Rheumatol 2004; 33: 108–14
   PubMed Web of Science ®Google Scholar
• Funauchi M., Sugishima H., Minoda M., Horiuchi A. Effect of interferon‐gamma on B lymphocytes of patients with systemic lupus erythematosus. J Rheumatol 1991; 18: 368–72
   PubMedGoogle Scholar
• Golbus J., Salata M., Greenwood J., Hudson J., Richardson B. C. Increased immunoglobulin response to gamma‐interferon by lymphocytes from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1988; 46: 129–40
   PubMedGoogle Scholar
• Riemekasten G., Langnickel D., Ebling F. M., Karpouzas G., Kalsi J., Herberth G., et al. Identification and characterization of SmD183‐119‐reactive T cells that provide T cell help for pathogenic anti‐double‐stranded DNA antibodies. Arthritis Rheum 2003; 48: 475–85
   PubMedGoogle Scholar
• Schorlemmer H. U., Dickneite G., Kanzy E. J., Enssle K. H. Modulation of the immunoglobulin dysregulation in GvH‐ and SLE‐like diseases by the murine IL‐4 receptor (IL‐4‐R). Inflamm Res 1995; 44(Suppl 2)S194–6
   Google Scholar
• Nakajima A., Hirose S., Yagita H., Okumura K. Roles of IL‐4 and IL‐12 in the development of lupus in NZB/W F1 mice. J Immunol 1997; 158: 1466–72
   PubMed Web of Science ®Google Scholar
• Deocharan B., Marambio P., Edelman M., Putterman C. Differential effects of interleukin‐4 in peptide induced autoimmunity. Clin Immunol 2003; 108: 80–8
   PubMed Web of Science ®Google Scholar
• Singh R. R., Saxena V., Zang S., Li L., Finkelmann F. D., Witte D. P., et al. Differential contribution of IL‐4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003; 170: 4818–25
   PubMed Web of Science ®Google Scholar
• Hagiwara E., Gourley M. F., Lee S., Klinman D. K. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin‐10:interferon‐gamma‐secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379–85
   PubMed Web of Science ®Google Scholar
• Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M. Continuous administration of anti‐interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 305–10
   PubMed Web of Science ®Google Scholar
• Llorente L., Zou W., Levy Y., Richaud‐Patin Y., Wijdenes J., Alcocer‐Varela J., et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839–44
   PubMed Web of Science ®Google Scholar
• Llorente L., Richaud‐Patin Y., Garcia‐Padilla C., Claret E., Jakez‐Ocampo J., Cardiel M. H., et al. Clinical and biologic effects of anti‐interleukin‐10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1790–800
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R., Haanen J., Spits H., Roncarolo M., te Velde A., Figdor C., et al. Interleukin 10 (IL‐10) and viral IL‐10 strongly reduce antigen‐specific human T cell proliferation by diminishing the antigen‐presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915–24
   PubMed Web of Science ®Google Scholar
• Moore K., de Waal Malefyt R., Coffman R., O'Garra A. Interleukin‐10 and the interleukin‐10 receptor. Annu Rev Immunol 2001; 19: 683–765
   PubMed Web of Science ®Google Scholar
• Riemekasten G., Langnickel D., Enghard P., Undeutsch R., Humrich J., Ebling F. M., et al. Intravenous injection of a d1 protein of the smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol 2004; 173: 5835–42
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Regulatory role of T cells producing both interferon gamma and interleukin 10 in persistent infection. J Exp Med 2001; 194: F53–7
   PubMed Web of Science ®Google Scholar
• Jacob C. O., McDevitt H. O. Tumour necrosis factor‐alpha in murine autoimmune ‘lupus’ nephritis. Nature 1988; 331: 356–8
   PubMed Web of Science ®Google Scholar
• Gordon C., Ranges G. E., Greenspan J. S., Wofsy D. Chronic therapy with recombinant tumor necrosis factor‐alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989; 52: 421–34
   PubMedGoogle Scholar
• Aringer M., Graninger W., Steiner G., Smolen J. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open label study. Arthritis Rheum 2004; 50: 3161–9
   PubMed Web of Science ®Google Scholar